Henan Lingrui Pharmaceutical Co., Ltd. Announcement on Pledge of Part of Major Shareholder's Shares

Log in to the Sina Finance app and search for 【Information Disclosure】 to view more review grades

Stock code: 600285 Stock abbreviation: Lingrui Pharmaceutical Announcement No.: 2026-006

Henan Lingrui Pharmaceutical Co., Ltd.

Announcement on a Partial Pledge of Shares by a Major Shareholder

The board of directors of the Company and all directors hereby guarantee that the contents of this announcement do not contain any false records, misleading statements, or material omissions, and assume legal responsibility for the truthfulness, accuracy, and completeness of the contents.

Key highlights:

● Henan Lingrui Group Co., Ltd. (hereinafter referred to as “Lingrui Group”) holds 121,817,898 shares of Henan Lingrui Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”), accounting for 21.48% of the Company’s total share capital. After this pledge of 550,000 shares, Lingrui Group has cumulatively pledged 37,900,000 shares of the Company, representing 31.11% of the number of shares it holds, and accounting for 6.68% of the Company’s total share capital.

● As of the date of disclosure of this announcement, the cumulative pledged number of shares held by Lingrui Group and its persons acting in concert is 37,900,000 shares, accounting for 6.68% of the Company’s total share capital.

Recently, the Company received a notice of share pledge from Lingrui Group. Lingrui Group pledged 550,000 shares of the Company it holds—unrestricted tradable shares—to the Xinxian Sub-branch of Henan Rural Commercial Bank Co., Ltd. The details are as follows:

I. Basic information on this share pledge

1. Basic information on this share pledge

■

2. The pledged shares are not used for any matters such as security or other arrangements for performance compensation in major asset restructuring, etc.

3. Cumulative pledged shares of the shareholders

As of the date of disclosure of this announcement, the cumulative pledged shares of Lingrui Group and its persons acting in concert are as follows:

■

Note: If there are any discrepancies in the figures above due to trailing digits, they are caused by rounding.

II. Other matters for explanation

This share pledge by Lingrui Group will not have an adverse impact on the Company’s principal business, financing credit lines and financing costs, or its ability to sustain operations. The pledge risk of Lingrui Group is controllable and will not lead to any change in the Company’s actual controlling rights, nor will it have an adverse impact on the Company’s production and operations, corporate governance, independence, etc.

The Company will continue to monitor the pledge status of shares held by the major shareholder and its persons acting in concert, strictly comply with relevant regulations, and promptly perform information disclosure obligations.

This announcement is hereby given.

Board of Directors of Henan Lingrui Pharmaceutical Co., Ltd.

March 25, 2026

Endless information and precise interpretation—available on the Sina Finance app